Drug Profile
Research programme: anxiety disorder therapeutics - Johnson & Johnson
Alternative Names: JNJ 5234801; NOP modulators - Johnson & JohnsonLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Johnson & Johnson
- Class Piperidines
- Mechanism of Action Nociceptin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Anxiety-disorders in USA
- 06 May 2004 Preclinical trials in Anxiety disorders in USA (unspecified route)